Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.40    3.60 (2.36%)
Bid:
156.20
Ask:
156.60
Spread: 0.40 (0.256%)
Market Cap: £895.10m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM / Interim Management Statement

27 Apr 2016 07:00

ELEMENTIS PLC - AGM / Interim Management Statement

ELEMENTIS PLC - AGM / Interim Management Statement

PR Newswire

London, April 26

27 April 2016

AGM / Interim Management Statement

Elementis plc (ELM.L, the “Company" or the “Group"), the Global Specialty Chemicals Company, today issues its Interim Management Statement for the three months ended 31 March 2016.

Commenting on the Company’s performance Group Chief Executive, Paul Waterman, said: “During my first two months at Elementis I have been impressed by the quality of our people and the resilience of our business model. This is best exemplified by the sustained level of contribution margins in Specialty Products, the relative stability of the Chromium business in North America and the Group’s strong cash generation. Although some markets continue to be challenging and we are cycling against a stronger first quarter in 2015, we are proactively managing our margins and cost base to ensure that our performance for the year remains in line with management expectations.”

In Specialty Products, sales performance in coatings and personal care was satisfactory, while currency and lower oilfield sales resulted in total sales being 7 per cent below the same period last year. The following comments by division refer to constant currency sales:

In coatings additives, sales in North America were similar to the previous year as sales of decorative products from the New Martinsville plant continued to make good progress, while industrial sales remained subdued due to the impact of the stronger dollar on consumer exports, as previously reported. Sales in Europe were 1 per cent higher, while sales in Asia Pacific were 1 per cent lower, following the destocking and adjustment that took place in the Chinese economy in the second quarter of 2015. Sales to Latin America represent 5 per cent of total coatings sales and were 9 per cent lower than the previous year due to economic weakness in that region, particularly in Brazil.

In personal care, sales were 4 per cent higher than the previous period, as the business continued to benefit from geographic expansion and new product sales.

Sales in oilfield drilling were broadly in line with the quarterly sales run rate experienced in the second half of 2015, following the sharp downturn in North American demand that took place in the early part of 2015. Consequently, sales for the current quarter were 37 per cent below the same quarter last year.

As anticipated, Chromium sales for the first quarter were 11 per cent lower than the previous year, as market conditions outside of North America continued to be challenging. Although sales in North America were lower by 5 per cent, this is largely due to order timing and sales for the first six months of the year are expected to be in line with the same period last year. Sales outside of North America were 19 per cent lower than the previous year, with volumes lower by 6 per cent and pricing lower by 13 per cent.

The Group’s balance sheet remains strong and is again expected to be in a net cash position at the end of the year which, under our dividend policy, will continue to provide shareholders with attractive returns.

ENDS

Enquiries:

Elementis Paul Waterman, Chief Executive Brian Taylorson, Finance Director+ 44 (0) 207 067 2999
FTI Consulting Deborah Scott Matthew Cole+ 44 (0) 203 727 1000
Date   Source Headline
2nd Aug 20227:00 amRNSHalf-year Report
1st Aug 202211:08 amRNSTotal Voting Rights
21st Jul 20223:14 pmRNSHolding(s) in Company
1st Jul 20229:47 amRNSTotal Voting Rights
20th Jun 20221:54 pmRNSHolding(s) in Company
17th Jun 20224:35 pmRNSPrice Monitoring Extension
3rd May 202210:27 amRNSTotal Voting Rights
3rd May 20227:00 amRNSCompany Secretary Change
26th Apr 202212:28 pmRNSResult of AGM
26th Apr 20227:00 amRNSAGM Trading Statement
5th Apr 20224:17 pmRNSDirector/PDMR Shareholding
23rd Mar 20223:52 pmRNSAdditional Listing
22nd Mar 20224:18 pmRNSAnnual Financial Report & Notice of AGM
15th Mar 20227:53 amRNSDirectorate Change
8th Mar 202212:18 pmRNSDirector/PDMR Shareholding
8th Mar 202212:17 pmRNSDirector/PDMR Shareholding
8th Mar 202211:47 amRNSHolding(s) in Company
8th Mar 202210:43 amRNSDirector/PDMR Shareholding
8th Mar 202210:39 amRNSDirector/PDMR Shareholding
7th Mar 20223:26 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSPreliminary results year ended 31 December 2021
1st Mar 20222:03 pmRNSDirector Declaration
1st Mar 202211:18 amRNSBlock listing Interim Review
18th Jan 20227:00 amRNSTrading Update
10th Jan 20221:20 pmRNSHolding(s) in Company
4th Jan 202211:48 amRNSTotal Voting Rights
1st Dec 202111:10 amRNSTotal Voting Rights
10th Nov 202112:20 pmRNSHolding(s) in Company
3rd Nov 202111:25 amRNSHolding(s) in Company
1st Nov 20211:44 pmRNSTotal Voting Rights
28th Oct 20217:00 amRNSQ3 Trading Update
19th Oct 20216:10 pmRNSDirector Declaration
5th Oct 20218:42 amRNSDirector Declaration
1st Sep 20219:49 amRNSBlock listing Interim Review
2nd Aug 202110:22 amRNSTotal Voting Rights
29th Jul 20217:00 amRNSDirectorate Change
29th Jul 20217:00 amRNSHalf-year Report
5th Jul 202110:15 amRNSTotal Voting Rights
25th Jun 20212:59 pmRNSHolding(s) in Company
23rd Jun 20212:56 pmRNSDirector Declaration
1st Jun 202110:06 amRNSTotal Voting Rights
13th May 20213:39 pmRNSResult of AGM
13th May 20217:00 amRNSAGM Trading Statement
22nd Apr 20213:26 pmRNSAdditional Listing
20th Apr 20214:18 pmRNSResponse to Innospec Inc. announcement
20th Apr 20212:36 pmRNSPress Speculation Re Possible Offer for Elementis
9th Apr 20215:15 pmRNSAnnual Financial Report
7th Apr 20215:31 pmRNSDirector/PDMR Shareholding
1st Apr 20218:49 amRNSDirector/PDMR Shareholding
30th Mar 20214:08 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.